Efficacy and safety of co-cultured autologous tumor antigen-loaded dendritic cells and cytokine-induced killer cells combined with routine therapy in the treatment of advanced retinoblastoma
CHANG Xiaowen1, WANG Jun2, SUN Yanfeng2, MIAO Lixia2, YUAN Hailian2, LIU Hongyan2, LI Yanshan2, YANG Xinji3, ZHANG Xianglan2, LIU Qiuling1, 2
1.Graduate School of Anhui Medical University, Hefei 230032, China; 2. Department of Pediatrics, 3. Department of Orbital Disease Research Institute,the General Hospital of the Chinese People’s Armed Police Forces, Beijing 100039, China
Abstract：Objective To evaluate the clinical efficacy and safety of co-cultured autologous tumor antigen-loaded dendritic cells (DC) and cytokine-induced killer cells (CIK) (Ag-DC-CIK) combined with routine therapy in the treatment of advanced retinoblastoma (RB). Methods 26 patients suffering from RB who were diagnosed as advanced RB in the General Hospital of the Chinese People’s Armed Police Forces between December 2011 and December 2014. 13 patients received Ag-DC-CIK combined with routine treatment (combination group). The other patients received routine therapy (routine group). Results The combination group totally received 67 cycles (134 times) Ag-DC-CIK therapy. At the end of the follow-up, all patients in combination group who suffered D got the opportunity of reserving eyes; 2 out of 4 patients who lost the opportunity of operation had surgery eventually. All the group D patients of routine group underwent enucleation. 1 out of 4 patients who lost the opportunity of operation had surgery eventually. CD3+, CD4+ , CD4+/CD8+ and CD3+ CD56+ proportion in the combination group was higher than in another group, CD8+ proportion in the combination group was lower than in the routine group, and the difference was statistically significant (P<0.05). Only one patient had a fever (37.8 ℃) during the therapy, and could return to normal itself. Both groups of patients’ hepatorenal function, blood biochemistry and ECG had no statistically significant differences. Conclusions Ag-DC-CIK combined with routine therapy in the treatment of advanced RB is efficient and safe.
常晓雯, 王军, 孙岩峰, 苗丽霞, 袁海莲, 刘红艳, 李彦珊, 杨新吉, 张向兰, 刘秋玲. 抗原负载DC-CIK细胞治疗晚期视网膜母细胞瘤的疗效及其安全性[J]. 武警医学, 2015, 26(7): 707-711.
CHANG Xiaowen, WANG Jun, SUN Yanfeng, MIAO Lixia, YUAN Hailian, LIU Hongyan, LI Yanshan, YANG Xinji, ZHANG Xianglan, LIU Qiuling. Efficacy and safety of co-cultured autologous tumor antigen-loaded dendritic cells and cytokine-induced killer cells combined with routine therapy in the treatment of advanced retinoblastoma. Med. J. Chin. Peop. Armed Poli. Forc., 2015, 26(7): 707-711.
Zhan H L, Gao X, Pu X Y, et al. A randomized controlled trial of postoperative tumor lysate-pulsed dendritic cells and cytokine-induced killer cells immunotherapy in patients with localized and locally advanced renal cell carcinoma [J]. Chin Med J (Engl), 2012, 125(21):3771-3777.
[2]
Yang L, Ren B, Li H, et al. Enhanced antitumor effects of DC-activated CIKs to chemotherapy treatment in a single cohort of advanced non-small-cell lung cancer patients [J]. Cancer Immunol Immunother, 2013, 62(1): 65-73.
Linn Murphree A. Intraocular retinoblastoma: the case for a new group classification [J]. Ophthalmol Clin North Am, 2005, 18(1): 41-53.
[5]
Chen R, Deng X, Wu H, et al. Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: a systematic review and meta-analysis [J]. Int Immunopharmacol, 2014, 22(2): 451-464.
[6]
Jkel C E,Hauser S,Rogenhofer S,et al.Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma [J]. Clin Dev Immunol, 2012,2012: 1-7.
[7]
Wang Y F, Kunda P E, Lin J W, et al. Cytokine-induced killer cells co-cultured with complete tumor antigen-loaded dendritic cells, have enhanced selective cytotoxicity on carboplatin-resistant retinoblastoma cells [J]. Oncol Rep, 2013, 29(5): 1841-1850.
[8]
Liu Q, Wang Y, Wang H, et al. Tandem therapy for retinoblastoma: immunotherapy and chemotherapy enhance cytotoxicity on retinoblastoma by increasing apoptosis [J]. J Cancer Res Clin Oncol, 2013, 139(8): 1357-1372.
Ren J, Di L, Song G, et al. Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences [J]. Clin Transl Oncol, 2013, 15(10): 780-788.
2015, Vol. 26 
